Background
Metformin therapy for type 2 diabetes mellitus has been shown to reduce total mortality rates compared with other antihyperglycemic treatments but is thought to increase the risk of lactic acidosis. The true incidence of fatal and nonfatal lactic acidosis associated with metformin use is not known.
Methods
A comprehensive search was performed to identify all comparative trials or observational cohort studies published between January 1, 1959, and March 31, 2002, that evaluated metformin therapy, alone or in combination with other treatments, for at least 1 month. The incidence of fatal and nonfatal lactic acidosis was recorded as cases per patient-years for metformin treatment and for placebo or other treatments. In a second analysis, lactate levels were measured as a net change from baseline or as mean treatment values for metformin and comparison groups.
Results
Pooled data from 194 studies revealed no cases of fatal or nonfatal lactic acidosis in 36 893 patient-years in the metformin group or in 30 109 patients-years in the nonmetformin group. Using Poisson statistics with 95% confidence intervals, the probable upper limit for the true incidence of lactic acidosis in the metformin and nonmetformin groups was 8.1 and 9.9 cases per 100 000 patient-years, respectively. There was no difference in lactate levels for metformin compared with placebo or other nonbiguanide therapies.
Conclusion
There is no evidence to date that metformin therapy is associated with an increased risk of lactic acidosis or with increased levels of lactate compared with other antihyperglycemic treatments if the drugs are prescribed under study conditions, taking into account contraindications.
METFORMIN hydrochloride is a biguanide that has been used to treat type 2 diabetes mellitus for more than 40 years.1,2 Aside from its effect on carbohydrate metabolism, metformin treatment is thought to have other positive effects, such as weight loss or stabilization of weight gain.3-5 In addition, results of the UK Prospective Diabetes Study6 indicate that metformin monotherapy leads to reductions in diabetes mellitus–related end points, in the diabetes mellitus–related mortality rate, and in the total mortality rate compared with insulin use, sulfonylurea therapy, or diet alone.
Lactic acidosis is a rare, potentially fatal metabolic condition that can occur whenever substantial tissue hypoperfusion and hypoxia exist.7,8 Lactic acidosis is characterized by an elevated blood lactate concentration (>45.0 mg/dL [>5.0 mmol/L]), decreased blood pH (<7.35), and electrolyte disturbances with an increased anion gap. An earlier biguanide, phenformin hydrochloride, was withdrawn from the market because it was associated with a reported rate of lactic acidosis of 40 to 64 cases per 100 000 patient-years.2,9 Metformin, however, differs from phenformin in molecular structure and pharmacokinetics and, unlike phenformin, is thought to enhance glucose oxidation without substantially affecting fasting lactate production in peripheral tissues.10,11
The true incidence of metformin-associated lactic acidosis is not known. Population-based studies9,12-14 have estimated a rate of 2 to 9 cases of lactic acidosis in metformin users per 100 000 person-years. However, most of the reported cases have occurred in patients with severe acute conditions, such as renal failure, that could in themselves have caused the lactic acidosis.14,15 To estimate the risk specifically attributable to metformin use, the background rate of lactic acidosis in patients with type 2 diabetes mellitus who are not treated with metformin was assessed and was found to be 9 cases per 100 000 person-years.15 This raises the question of whether patients with type 2 diabetes mellitus have an increased risk for developing lactic acidosis with metformin use compared with other glucose-lowering treatments.
Metformin use is now considered to be contraindicated in many chronic conditions that may increase the risk of tissue anoxia and the development of lactic acidosis, such as cardiovascular, renal, pulmonary, and liver disease. These restrictions significantly reduce the number of patients who could benefit from metformin treatment. The objective of this review is to assess the risk of fatal and nonfatal lactic acidosis associated with metformin use in persons with type 2 diabetes mellitus compared with placebo or other glucose-lowering therapies. Another objective is to evaluate levels of blood lactate, measured at baseline and during treatment, for metformin treatment compared with placebo or other hypoglycemic therapies. An earlier version of this analysis was published as a review on The Cochrane Library.16
Trial search and selection
A comprehensive search through March 31, 2002, was performed of the Cochrane Library (including the Cochrane Controlled Trials Database), MEDLINE, OLDMEDLINE, Database of Abstracts of Reviews of Effectiveness, Reactions, and EMBASE using the terms "diabetes mellitus," "non-insulin-dependent," "NIDDM,"
"non insulin* dep*," "noninsulin* dep*," "non insulin dep*," "typ* II diabet*,"
"typ* 2 diabet*," "diabet* typ* 2," "diabet* typ* II," "biguanides," "biguanid*,"
"metformin," "glucophag*," and "metformin*." Studies published in any language were included. The search was further augmented by scanning references of identified articles and reviews, abstracts at clinical symposia, and the Cumulated Index Medicus. In addition, attempts were made to contact authors of identified studies and manufacturers of metformin to obtain additional information.
Two independent reviewers (G.A.P. and S.R.S.) reviewed every record found in the search, and articles on metformin use in patients with diabetes mellitus were retrieved. Two investigators (S.R.S. and E.G.) independently evaluated studies for inclusion, and the observed percentage agreement between raters was measured using the κ statistic.17
Prospective clinical trials of at least 1 month in duration were included if they evaluated metformin use, alone or in combination with other treatments, compared with placebo or compared with any other glucose-lowering therapy for type 2 diabetes mellitus. In addition, all observational cohort studies evaluating at least 1 month of metformin use were included in the analysis if they provided the number of patients and the duration of treatment. The excluded trials lasting less than 1 month were evaluated separately to see whether there were any cases of lactic acidosis.
Interventions studied included metformin, alone or in combination with other treatments, vs placebo or another antihyperglycemic intervention, such as diet, insulin, or sulfonylureas. Data on participants treated with phenformin were not included in the analysis for lactic acidosis but were included in measurements of lactate levels.
The methodological quality of each study was evaluated based on the quality criteria modified from Schulz,18 Jadad,19 and Stroup20 and their colleagues. Studies were divided into 5 categories that characterize the treatment of metformin in the trials. A score of A, B, or C was given to randomized controlled trials using the following factors: (1) Was the study randomized? If so, was the randomization procedure adequate? (2) Were the patients and people administering the treatment masked to the intervention? (3) Were withdrawals and dropouts described? A score of D was given to open-label nonrandomized controlled trials, and a score of E was given to observational cohort studies.
Each trial was assessed independently by 2 reviewers (S.R.S. and E.G.), and consensus was reached in cases of disagreement. Interrater agreement before consensus was calculated using the κ statistic.
Data extraction and data synthesis
Two independent reviewers (S.R.S. and E.G.) extracted data from the selected articles, reconciling differences by consensus. Outcomes measured were (1) death described as due to lactic acidosis; (2) reported cases of nonfatal lactic acidosis, as defined by the investigator; and (3) blood lactate levels for metformin compared with placebo or other nonbiguanide therapies and compared with phenformin.
The treatment effect for fatal and nonfatal lactic acidosis was expressed as a risk difference by taking the incidence of events during metformin, alone or in combination with other treatments, and then subtracting the incidence of events during placebo or alternative treatments. As no cases of lactic acidosis were found, the probable upper limits for the true incidence of lactic acidosis in the metformin and nonmetformin groups were calculated separately using Poisson statistics. Information was obtained on how many patients were older than 65 years or were thought to have concomitant hypoxemic conditions.
Once pooled results revealed no cases of lactic acidosis, it was decided to report on randomized controlled trials that measured blood lactate levels for metformin use compared with placebo or nonbiguanide treatments and also compared with phenformin use. Three outcomes were analyzed for the metformin group compared with the comparison groups: (1) the change in lactate levels from baseline to treatment, (2) the mean lactate levels recorded during treatment, and (3) the change in treatment lactate levels from a basal state to peak stimulation with either food or exercise. The results were recorded as the weighted mean difference (WMD) and were pooled using the fixed-effects model for continuous data.
The electronic database search identified 638 articles, 191 of which were potentially relevant studies on metformin use in patients with type 2 diabetes mellitus. After scanning abstracts from symposia and references from selected articles, an additional 70 studies were identified. Of these 261 studies, 193 met the inclusion criteria.6,10,21-5354-9596-125126-159160-202203-211 One additional unpublished trial (2001) was received from Evertine Abbink, MD. The κ score for interrater agreement in trial selection was 0.87 (95% confidence interval [CI], 0.76-0.98), indicating good agreement, and consensus was reached on the remaining trials.
Of the 194 studies included in the analysis, 126 were prospective comparative trials, 56 were prospective cohort studies, and 12 were retrospective cohort studies. A total of 56 692 participants were followed for 67 002 patient-years, with 18 689 participants (36 893 patient-years) in the metformin group and 38 003 participants (30 109 patient-years) in the nonmetformin group. The mean ± SD age of the participants in the metformin group was 57.1 ± 8.9 years, and 61% were men. In the nonmetformin group, the mean ± SD age was 57.2 ± 9.1 years, and 61% were men. The mean trial duration was 2.1 years (range, 0.08-10.7 years). The mean study size in the metformin group was 55 participants (range, 6-683). The mean study size in the nonmetformin group was 76 participants (range, 8-1362). The dropout rate was estimated to be 9.3%.
Metformin was given in daily doses of 1 to 3 g, with the dosage titrated clinically. Comparison treatments included placebo, diet, insulin, glyburide, gliclazide, glipizide, glibenclamide, glimepiride, chlorpropamide, tolbutamide, acarbose, nateglinide, repaglinide, miglitol, troglitazone, rosiglitazone maleate, and guar gum.
No trial was specifically designed to assess the incidence of lactic acidosis, but adverse effects or adverse events were described in almost all of the trials. Attempts were made to reach the authors of the trials, and those who responded confirmed that there were no known cases of fatal or nonfatal acidosis in their trials. Serum bicarbonate or lactate levels were measured in 96 of the included studies (49%). Of the comparative trials, 26 measured lactate levels during metformin and nonmetformin treatment.
Studies were excluded for the following reasons: 2 were retrospective and 13 were prospective cohort studies that did not give information on the number of patients or the length of treatment, 39 prospective comparative trials were less than 1 month in duration, and 13 were retrospective analyses or reviews.
Methodological quality of included studies
Of the trials analyzed, 3 received a score of A; 40, a score of B; 55, a score of C; 28, a score of D; and 68, a score of E. The κ score for interrater agreement was 0.83 (95% CI, 0.75-0.91), indicating good agreement.
Quantitative data synthesis
Incidence of Lactic Acidosis
When combining the data from cohort studies with the prospective comparative trials (including data from the unpublished data from E. J. Abbink, MD, 2001), 6,10,21-4243-6667-7172-7879-8182-101102-134135-161162-182183-203204-211 there were no cases of fatal or nonfatal lactic acidosis reported in the metformin group (36 893 patient-years) or in the nonmetformin group (30 109 patient-years). Using Poisson statistics with 95% CIs, the probable upper limit for the true incidence of lactic acidosis in the metformin group is 8.1 cases per 100 000 patient-years and in the nonmetformin group is 9.9 cases per 100 000 patient-years.
Of the 182 prospective studies,6,10,21-25,28,29,31-39,41,4243,44,46-6667-7172-7879-8182-101102,103,105-108,110-134135-148,150-161162-165,168-171,173-182183-203204-211 80 (44%) allowed for the inclusion of renal insufficiency, following 16 233 patient-years of metformin use, and 174 (96%) allowed for the inclusion of at least 1 of the contraindications listed herein. It was estimated from the available data that 16% of the participants in the studies were older than 65 years, and they were followed for approximately 5903 patient-years of metformin use.
For randomized controlled trials10,36,38,44,47,58,84,112,117,178 that provided the data, the baseline lactate level measured before metformin treatment was 10.2 ± 2.3 mg/dL (1.1 ± 0.2 mmol/L). There was no difference in the net change in lactate levels from baseline for metformin treatment compared with placebo or nonbiguanide therapies, with a WMD of 1.0 mg/dL (0.11 mmol/L) (95% CI, −0.1 to 2.2 mg/dL [−0.01 to 0.24 mmol/L]) (Figure 1). The mean ± SD lactate level during metformin treatment was 11.2 ± 2.8 mg/dL (1.2 ± 0.3 mmol/L), which was not significantly different from nonbiguanide comparisons (WMD, 0.5 mg/dL [0.06 mmol/L]; 95% CI, 0 to 1.2 mg/dL [0 to 0.1 mmol/L]), and was 6.8 mg/dL (0.8 mmol/L) lower than with phenformin use (95% CI, −7.9 to −5.9 mg/dL (−0.9 to −0.6 mmol/L]) (Figure 2). The mean ± SD lactate level during metformin treatment, measured before and after stimulation by a meal or strenuous exercise, was 20.7 ± 15.3 mg/dL (2.3 ± 1.7 mmol/L) (Figure 3). This value was not significantly different from that of the metformin group vs the nonbiguanide group (WMD, 0.8 mg/dL [0.1 mmol/L]; 95% CI, −0.3 to 2.0 mg/dL [−0.03 to 0.2 mmol/L]) or the phenformin group (WMD, −3.3 mg/dL [−0.4 mmol/L]; 95% CI, −9.5 to 2.9 mg/dL [−1.1 to 0.3 mmol/L]). Five trials62,73,82,152,195 that measured lactate levels did not provide data to be analyzed but reported levels to be normal during metformin and nonmetformin treatment.
Possible heterogeneity was noted in the 3 trials38,58,139 that measured lactate levels after stimulation by food or exercise. The results were not significantly different when the random-effects model was used (WMD, 0.4 mg/dL [0.04 mmol/L]; 95% CI, −4.1 to 4.8 mg/dL (−0.4 to 0.5 mmol/L]). In addition, some heterogeneity was noted in the 3 trials measuring mean lactate levels for metformin treatment compared with phenformin treatment. When the random-effects model was used, the difference was no longer statistically significant (−5.8 mg/dL [−0.6 mmol/L]; 95% CI, −14.7 to 3.2 mg/dL [−1.6 to 0.4 mmol/L]).
Funnel plots of the effect size vs SE were evaluated for the included trials10,36,38,44,47,58,60,67,83,101,105,112,117,129,137,145,178,182,207 that measured lactate levels. No evidence of significant small study publication bias was found.
To evaluate the risk of lactic acidosis attributed to metformin use, pooled data from all known prospective comparative trials and observational cohort studies lasting longer than 1 month were analyzed. No cases were found in 194 trials with 36 893 patient-years of metformin treatment. In fact, on review of 56 additional trials that were excluded from analysis (those that lasted <1 month or were of unclear duration), no cases of lactic acidosis were found. Using Poisson statistics, the probable upper limit for the true incidence of lactic acidosis associated with metformin use is 8.1 cases per 100 000 patient-years and with other nonbiguanide treatments is 9.9 cases per 100 000 patient-years. Of the trials that measured blood lactate levels, there was no significant difference for metformin treatment compared with placebo or nonbiguanide treatments, and levels were lower for metformin treatment than for phenformin treatment (WMD, −6.8 mg/dL [−0.75 mmol/L]; 95% CI, −7.9 to −5.9 mg/dL [−0.86 to −0.65 mmol/L]).
The mean duration of studies included in this review was 2.1 years (range, 1 month to 10.7 years). In addition, excluded trials of less than 1 month in duration were evaluated to see whether lactic acidosis occurs shortly after initiation of treatment, and no cases were found.
This review has several limitations. Essentially, all the data included in this analysis were from published trials, and this may have produced biased results. A funnel plot of effect size vs SE did not provide evidence for significant publication bias, since no cases were found in any trial. Many of the comparative trials included in the analysis were sponsored by pharmaceutical companies producing antihyperglycemic medications other than metformin, in which case a bias may be to publish adverse effects for metformin.
Another difficulty is that to assess the risk of a rare occurrence such as lactic acidosis, it may be necessary to evaluate more than 36 000 patient-years of metformin treatment. It is especially difficult to assess the risk of lactic acidosis in the presence of standard contraindications such as renal or hepatic insufficiency because it is unclear exactly how many of the participants had these conditions, and it is possible that the number of participants with these conditions may have been too small to detect an effect. For that reason, no conclusions can be made about the safety of metformin use in the presence of these conditions. Despite these limitations, the most important conclusion from this review is that, at present, there is no evidence from prospective comparative trials or observational cohort studies to support the hypothesis that metformin treatment is associated with an increased risk of lactic acidosis compared with other antihyperglycemic treatments.
Metformin treatment in overweight patients with type 2 diabetes mellitus has been shown to reduce cardiovascular and total mortality rates compared with insulin use, sulfonylurea use, or diet alone.6 Concern about the risk of lactic acidosis has led to recommendations that metformin therapy be withheld in persons with chronic conditions that in themselves can cause lactic acidosis. These recommendations, if followed, would reduce the number of patients eligible to receive metformin by approximately half.15 It has been found that in clinical practice these standard contraindications are largely disregarded, with 54% to 73% of patients taking metformin having at least 1 contraindication to treatment.11,212 In a cross-sectional study,212 19% of patients taking metformin who were admitted to a hospital had concurrent renal insufficiency.
Metformin treatment has been implicated as a cause of lactic acidosis because treatment with a related biguanide, phenformin, had been associated with several cases of lactic acidosis, and phenformin was removed from the US market in 1977.213 Despite their similarities, phenformin has a chemical structure substantially different than that of metformin. Unlike metformin, phenformin can impair oxidative phosphorylation in the liver, thereby increasing lactate production by anaerobic pathways.47,182,214-216 In contrast, metformin inhibits hepatic gluconeogenesis without altering lactate turnover or lactate oxidation.10,217,218 In addition to the trials analyzed in this review, several other trials have confirmed that metformin treatment does not significantly elevate blood lactate levels, even in the presence of renal impairment or advanced age.77,118,133,214,215,219-222
Now, the only evidence to indicate that metformin use is associated with lactic acidosis comes from reports of approximately 330 cases that have occurred in patients taking metformin.223-226 Lactic acidosis has also been reported in patients with diabetes mellitus not treated with metformin, typically under conditions in which there is significant tissue hypoperfusion or hypoxia.213 One study15 found that the rate of confirmed lactic acidosis in the United States, measured before the introduction of metformin and after the withdrawal of phenformin, was approximately 10 per 100 000 patient-years, which is equivalent to that thought to be associated with metformin treatment. Another study213 evaluated all cases of nonketotic metabolic acidosis in patients with type 2 diabetes mellitus that occurred during 609 emergency admissions to a university hospital. The rates of nonketotic acidosis per 1000 emergency admissions were 29 for sulfonylurea use, 32 for sulfonylurea plus phenformin use, 48 for insulin use, and 0 for metformin treatment. All cases of nonketotic metabolic acidosis found were associated with severe precipitant disease that could have caused lactic acidosis. The investigators conclude that it is the underlying systemic dysfunction and not the particular treatment that is the main determinant for the appearance of lactic acidosis. In support of that conclusion, the results of this review reveal that there is no evidence of an increased risk of lactic acidosis associated with metformin use if it is prescribed under the study conditions, taking into account contraindications.
Corresponding author and reprints: Shelley R. Salpeter, MD, Santa Clara Valley Medical Center, 751 S Bascom Ave, San Jose, CA 95128 (e-mail: salpeter@stanford.edu).
Accepted for publication January 8, 2003.
This study was supported by Santa Clara Valley Medical Center (Drs S. R. Salpeter, Greyber, and Pasternak).
We thank Christine Clar, MD, and Bernd Richter, MD, for guidance with the Cochrane Review, Rikke Greenwald for coordinating the trial search, and Donald Miller for assisting with the graphics.
1.Sterne
J Treatment of diabetes mellitus with N.N. dimethyl guanil guanidine (LA 6023, glucophage).
Therapie. 1959;14625- 630
Google Scholar 3.Campbell
IWHowlett
HCS Worldwide experience of metformin as an effective glucose-lowering agent: a meta-analysis.
Diabetes Metab Rev. 1995;11
((suppl 1))
S57- S62
PubMedGoogle ScholarCrossref 4.Guthrie
R Treatment of non–insulin-dependent diabetes mellitus with metformin.
J Am Board Fam Pract. 1997;10213- 221
PubMedGoogle Scholar 6.UK Prospective Diabetes Study (UKPDS) Group, Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).
Lancet. 1998;352854- 865
PubMedGoogle ScholarCrossref 10.Cusi
KConsoli
ADeFronzo
RA Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus.
J Clin Endocrinol Metab. 1996;814059- 4067
PubMedGoogle Scholar 12.Campbell
IW Metformin and the sulphonylureas: the comparative risk.
Horm Metab Res Suppl. 1985;15105- 111
PubMedGoogle Scholar 14.Misbin
RIGreen
LStadel
BV
et al. Lactic acidosis in patients with diabetes treated with metformin.
N Engl J Med. 1998;338265- 266
PubMedGoogle ScholarCrossref 16.Salpeter
SGreyber
EPasternak
GSalpeter
E Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.
The Cochrane Library [serial online]. Oxford, England Update Software2002;
(issue 2.)
Google Scholar 17.Fleiss
JL Statistical Methods for Rates and Proportions. 2nd ed. New York, NY John Wiley & Sons Inc1981;217- 234
18.Schulz
KFChalmers
IHayes
RJAltman
DG Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials.
JAMA. 1995;273408- 412
PubMedGoogle ScholarCrossref 19.Jadad
ARMoore
ACarroll
D
et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?
Control Clin Trials. 1996;171- 12
PubMedGoogle ScholarCrossref 20.Stroup
DFBerlin
JAMorton
SC
et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting.
JAMA. 2000;2832008- 2012
PubMedGoogle ScholarCrossref 21.Aarsand
AKCarlsen
SM Folate administration reduces circulating homocysteine levels in NIDDM patients on long-term metformin treatment.
J Intern Med. 1998;244169- 174
PubMedGoogle ScholarCrossref 22.Abbasi
FKamath
VRizvi
AA
et al. Results of a placebo-controlled study of the metabolic effects of the addition of metformin to sulfonylurea-treated patients: evidence for a central role of adipose tissue.
Diabetes Care. 1997;201863- 1869
PubMedGoogle ScholarCrossref 23.Abbasi
FCarantoni
MChen
YDReaven
GM Further evidence for a central role of adipose tissue in the antihyperglycemic effect of metformin.
Diabetes Care. 1998;211301- 1305
PubMedGoogle ScholarCrossref 24.Abbink
EJTack
CJPickkers
P
et al. Vascular effects of glibenclamide, glimepiride, metformin and acarbose in type 2 DM patients [abstract].
Diabetologia. 2000;43
((suppl 1))
A39
Google Scholar 25.Aguilar
CAWong
BGomez-Perez
FJRull
JA Combination daytime chlorpropamide-metformin/bedtime insulin in the treatment of secondary failures in non insulin dependent diabetes.
Rev Invest Clin. 1992;4471- 76
PubMedGoogle Scholar 26.Allen
GEMontgomery
DADWeaver
JA Dimethylbiguanide in the treatment of diabetes mellitus [in French].
Rev Franc Endocrinol Clin. 1961;2347- 352
Google Scholar 27.Andras
KTamas
HGyorgy
K Experience with biguanide treatment for diabetes mellitus [in Polish].
Orv Hetil. 1962;1031029- 1032
Google Scholar 28.Aviles-Santa
LSinding
JRaskin
P Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial.
Ann Intern Med. 1999;131182- 188
PubMedGoogle ScholarCrossref 29.Azerad
ELasry
M Treatment of diabetes with NN-dimethyl biguanide [in French].
Gaz Med Fr. 1960;11555- 1558
Google Scholar 30.Bacci
LCassarini
F N.N. dimethyl-biguanide (DMGG) in the treatment of diabetes mellitus [in Italian].
Minerva Med. 1961;522770- 2773
Google Scholar 31.Bayraktar
MVan Thiel
DHAdalar
N A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients.
Diabetes Care. 1996;19252- 254
PubMedGoogle ScholarCrossref 32.Beisswenger
PJHowell
SKTouchette
AD
et al. Metformin reduces systemic methylglyoxal levels in type 2 diabetes.
Diabetes. 1999;48198- 202
PubMedGoogle ScholarCrossref 33.Bell
DSHMayo
MS Outcome of metformin-facilitated reinitiation of oral diabetic therapy in insulin-treated patients with non-insulin-dependent diabetes mellitus.
Endocr Pract. 1997;373- 76
Google ScholarCrossref 34.Beyer
G Results in the treatment of diabetes with glucophage retard [in German].
Ther Ggw. 1975;1141426- 1437
PubMedGoogle Scholar 35.Bingle
JPJames
JI Metformin combined with chlorpropamide in the treatment of diabetes mellitus.
Practitioner. 1964;192567- 572
Google Scholar 36.Bjorntorp
PCarlstrom
SFagerberg
SE
et al. Influence of phenformin and metformin on exercise induced lactataemia in patients with diabetes mellitus.
Diabetologia. 1978;1595- 98
PubMedGoogle ScholarCrossref 37.Boronat
CMMerrero
ADLa Roche
BF
et al. Effectiveness of treatment with metformin in patients with type 2 diabetes mellitus poorly controlled with insulin treatment [in Spanish].
Rev Clin Esp. 2000;20074- 76
PubMedGoogle ScholarCrossref 38.Botha
JIViking
AIJackson
WP Association of lactic acidosis with biguanide therapy [letter].
S Afr Med J. 1977;52301- 302
Google Scholar 39.Boyd
KRogers
CBoreham
C
et al. Insulin, glibenclamide or metformin treatment for non insulin dependent diabetes: heterogeneous responses of standard measures of insulin action and insulin secretion before and after differing hypoglycaemic therapy.
Diabetes Res. 1992;1969- 76
PubMedGoogle Scholar 41.Cairns
SAShalet
SMarshall
AJHartog
M A comparison of phenformin and metformin in the treatment of maturity onset diabetes.
Diabete Metab. 1977;3183- 188
PubMedGoogle Scholar 42.Calle-Pascual
AIGarcia-Honduvilla
JMartin-Alvarez
PJ
et al. Comparison between acarbose, metformin, and insulin treatment in type 2 diabetic patients with secondary failure to sulfonylurea treatment.
Diabete Metab. 1995;21256- 260
PubMedGoogle Scholar 43.Campbell
IWMenzies
DGMcBain
AMBrown
IRF Effects of metformin on blood pressure and microalbuminuria in diabetes mellitus.
Diabete Metab. 1988;14613- 617
Google Scholar 44.Campbell
IWMenzies
DGChalmers
J
et al. One year comparative trial of metformin and glipizide in type 2 diabetes mellitus.
Diabete Metab. 1994;20394- 400
PubMedGoogle Scholar 45.Canivet
JRoux
P The treatment of diabetes mellitus: statistical results after a review of 1190 cases [in French].
Presse Med. 1962;702038- 2040
Google Scholar 46.Carpentier
JLuyckx
ASLefebvre
PJ Influence of metformin on arginine-induced glucagon secretion in human diabetes.
Diabete Metab. 1975;123- 28
PubMedGoogle Scholar 47.Cavallo-Perin
PAluffi
EEstivi
P
et al. The hyperlactatemic effect of biguanides: a comparison between phenformin and metformin during a 6-month treatment.
Riv Eur Sci Med Farmacol. 1989;1145- 49
PubMedGoogle Scholar 48.Chakrabarti
RHocking
EDFearnley
GR Fibrinolytic effect of metformin in coronary-artery disease.
Lancet. 1965;19256- 259
Google ScholarCrossref 49.Chan
JCTomlinson
BCritchley
JA
et al. Metabolic and hemodynamic effects of metformin and glibenclamide in normotensive NIDDM patients.
Diabetes Care. 1993;161035- 1038
PubMedGoogle ScholarCrossref 50.Chiasson
J-LJosse
RGHunt
JA
et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus: a multicenter controlled clinical trial.
Ann Intern Med. 1994;121928- 935
PubMedGoogle ScholarCrossref 51.Chiasson
J-LNaditch
L The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes.
Diabetes Care. 2001;24989- 994
PubMedGoogle ScholarCrossref 52.Cho
YWYang
DHOh
DY
et al. Plasma t-PA and PAl-1 antigen concentrations in non-insulin dependent diabetic patients: effects of treatment modality on fibrinolysis.
Korean J Intern Med. 1992;781- 86
PubMedGoogle Scholar 53.Clarke
BFDuncan
LJP Combined metformin-chlorpropamide therapy in 108 diabetic sulphonylurea-failures.
Lancet. 1965;11248- 1251
Google ScholarCrossref 54.Clarke
BFDuncan
LJ Comparison of chlorpropamide and metformin treatment on weight and blood-glucose response of uncontrolled obese diabetics.
Lancet. 1968;1123- 126
PubMedGoogle ScholarCrossref 55.Clarke
BCampbell
IW Comparison of metformin and chlorpropamide in non-obese, maturity-onset diabetics uncontrolled by diet.
BMJ. 1977;21576- 1578
PubMedGoogle ScholarCrossref 56.Collier
AWatson
HHPatrick
AW
et al. Effect of glycaemic control, metformin and gliclazide on platelet density and aggregability in recently diagnosed type 2 (non-insulin-dependent) diabetic patients.
Diabete Metab. 1989;15420- 425
PubMedGoogle Scholar 57.D'Argenzio
RCavallo
PMerante
DMorelli
A Comparison of two treatment models in type-II diabetic patients with poor metabolic control: preformed combination of glibenclamide 2,5 mg + metformin 400 mg or mono-therapy with sulfonylurea at maximal doses? an evaluation at six months.
Minerva Endocrinol. 1996;21101- 110
PubMedGoogle Scholar 58.Damsbo
PHermann
LSVaag
A
et al. Irreversibility of the defect in glycogen syntheses activity in skeletal muscle from obese patients with NIDDM treated with diet and metformin.
Diabetes Care. 1998;211489- 1494
PubMedGoogle ScholarCrossref 59.Davidson
JMooradian
APiper
B Effect of metformin/glyburide tablets on HBA1c in first-line treatment of type 2 diabetes [abstract].
Diabetologia. 2000;43
((suppl 1))
A184
Google Scholar 60.De Silva
SRBetteridge
DJShawe
JEH
et al. Metformin and clofibrate in maturity onset diabetes mellitus: advantages of combined treatment.
Diabete Metab. 1979;5223- 229
PubMedGoogle Scholar 61.DeFronzo
RABarzilai
NSimonson
D Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects.
J Clin Endocrinol Metab. 1991;731294- 1301
PubMedGoogle ScholarCrossref 62.DeFronzo
RAGoodman
AM Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus: the Multicenter Metformin Study Group.
N Engl J Med. 1995;333541- 549
PubMedGoogle ScholarCrossref 63.Dies
HLozano Castaneda
OGarcia Viveros
M
et al. Long range results (5 years) in the treatment of stable diabetes with low doses of clorpropamide-metformin (author's transl) [in Spanish].
Rev Invest Clin. 1978;30131- 134
PubMedGoogle Scholar 64.Donnelly
P Dimethyldiguanide in diabetes mellitus: report of a small trial.
J Ir Med Assoc. 1960;47142- 145
Google Scholar 65.Dornan
TIHeller
SRPeck
GM
et al. Double-blind evaluation of efficacy and tolerability of metformin in NIDDM.
Diabetes Care. 1991;14342- 344
PubMedGoogle ScholarCrossref 66.Elkeles
RS The effects of oral hypoglycaemic drugs on serum lipids and lipoproteins in non-insulin-dependent diabetes (NIDDM).
Diabete Metab. 1991;17
((pt 2))
197- 200
PubMedGoogle Scholar 67.Erle
GLovise
SStocchiero
C
et al. A comparison of preconstituted, fixed combinations of low-dose glyburide plus metformin versus high-dose glyburide alone in the treatment of type 2 diabetic patients.
Acta Diabetol. 1999;3661- 65
PubMedGoogle ScholarCrossref 68.Fanghanel
GSanchez-Reyes
LTrujillo
C
et al. Metformin's effects on glucose and lipid metabolism in patients with secondary failure to sulfonylureas.
Diabetes Care. 1996;191185- 1189
PubMedGoogle ScholarCrossref 69.Fanghanel
GSilva
USanchez-Reyes
L
et al. Effects of metformin on fibrinogen levels in obese patients with type 2 diabetes.
Rev Invest Clin. 1998;50389- 394
PubMedGoogle Scholar 70.Ferner
RERawlins
MDAlberti
KG Impaired β-cell responses improve when fasting blood glucose concentration is reduced in non-insulin-dependent diabetes.
Q J Med. 1988;66137- 146
PubMedGoogle Scholar 71.Fisman
EZTennenbaum
ABoyko
V
et al. Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up.
Clin Cardiol. 2001;24151- 158
PubMedGoogle ScholarCrossref 72.Fonseca
VRosenstock
JPatwardhan
RSalzman
A Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.
JAMA. 2000;2831695- 1702
PubMedGoogle ScholarCrossref 73.Fritsche
ASchmulling
RMHaring
HUStumvoll
M Intensive insulin therapy combined with metformin in obese type 2 diabetic patients.
Acta Diabetol. 2000;3713- 18
PubMedGoogle ScholarCrossref 74.Galeone
FFiore
GArcangeli
AMannucci
E Gliclazide and metformin combination in patients with type 2 diabetes: preliminary data [in Italian].
Minerva Endocrinol. 1998;2371- 75
PubMedGoogle Scholar 75.Garber
AJDuncan
TGGoodman
AM
et al. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial.
Am J Med. 1997;103491- 497
PubMedGoogle ScholarCrossref 76.Garcia Viveros
MPrado Vega
RRull
JALozano-Castaneda
O Chlorpropamide-metformin in obese diabetics or diabetics with side effects from sulfonylureas: 2-year results [in Spanish].
Prensa Med Mex. 1971;36347- 349
PubMedGoogle Scholar 77.Giugliano
DQuatraro
AConsoli
G
et al. Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors.
Eur J Clin Pharmacol. 1993;44107- 112
PubMedGoogle ScholarCrossref 79.Grant
PJStickland
MHBooth
NAPrentice
CR Metformin causes a reduction in basal and post-venous occlusion plasminogen activator inhibitor-1 in type 2 diabetic patients.
Diabet Med. 1991;8361- 365
PubMedGoogle ScholarCrossref 80.Grant
PJ The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes.
Diabetes Care. 1996;1964- 66
PubMedGoogle ScholarCrossref 81.Grant
PJ Metformin reduces circulating factor VII concentrations in patients with type 2 diabetes mellitus.
Thromb Haemost. 1998;80209- 210
PubMedGoogle Scholar 82.Gregorio
FAmbrosi
FAngelici
F
et al. Body mass index, blood lactate and therapeutic effectiveness of metformin in type II diabetes mellitus.
Medicina (Firenze). 1989;9200- 204
PubMedGoogle Scholar 83.Gregorio
FAmbrosi
FMarchetti
P
et al. Low dose metformin in the treatment of type II non-insulin-dependent diabetes: clinical and metabolic evaluations.
Acta Diabetol Lat. 1990;27139- 155
PubMedGoogle ScholarCrossref 84.Gregorio
FAmbrosi
FManfrini
S
et al. Metformin, plasma glucose and free fatty acids in type II diabetic out-patients: results of a clinical study.
Diabetes Res Clin Pract. 1997;3721- 33
PubMedGoogle ScholarCrossref 85.Groop
LWiden
EFranssila-Kallunki
A
et al. Different effects of insulin and oral antidiabetic agents on glucose and energy metabolism in type 2 (non-insulin-dependent) diabetes mellitus.
Diabetologia. 1989;32599- 605
PubMedGoogle ScholarCrossref 86.Groop
LWiden
E Treatment strategies for secondary sulfonylurea failure: should we start insulin or add metformin? is there a place for intermittent insulin therapy?
Diabete Metab. 1991;17
((pt 2))
218- 223
PubMedGoogle Scholar 87.Guillausseau
PJ Monitoring of metabolic control in patients with non-insulin-dependent diabetes mellitus on oral hypoglycaemic agents: value of evening blood glucose determination.
Diabet Med. 1997;14798- 802
PubMedGoogle ScholarCrossref 88.Gursoy
NIlcol
YTuncel
E
et al. The effect of metformin on insulin resistance and serum lipid profiles [abstract].
Diabetologia. 2000;43
((suppl 1))
A150
Google Scholar 89.Haupt
EKnick
BKoschinsky
T
et al. Oral antidiabetic combination therapy with sulphonylureas and metformin.
Diabete Metab. 1991;17
((pt 2))
224- 231
PubMedGoogle Scholar 90.Herman
JBJackson
WPU Dimethyldiguanide (glucophage, LA 6023) in diabetes mellitus.
S Afr Med J. 1961;35286- 288
Google Scholar 91.Hermann
LSBitzen
POKjellstrom
T
et al. Comparative efficacy of metformin and glibenclamide in patients with non-insulin-dependent diabetes mellitus.
Diabete Metab. 1991;17
((pt 2))
201- 208
PubMedGoogle Scholar 92.Hermann
LSKarlsson
JESjostrand
A Prospective comparative study in NIDDM patients of metformin and glibenclamide with special reference to lipid profiles.
Eur J Clin Pharmacol. 1991;41263- 265
PubMedGoogle ScholarCrossref 93.Hermann
LSSchersten
BMelander
A Antihyperglycaemic efficacy, response prediction and dose-response relations of treatment with metformin and sulphonylurea, alone and in primary combination.
Diabet Med. 1994;11953- 960
PubMedGoogle ScholarCrossref 94.Hermann
LSSchersten
BBitzen
PO
et al. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations: a double-blind controlled study.
Diabetes Care. 1994;171100- 1109
PubMedGoogle ScholarCrossref 95.Higginbotham
LMartin
FIR Double-blind trial of metformin in the therapy of non-ketotic diabetics.
Med J Aust. 1979;2154- 156
Google Scholar 97.Hoffmann
JSpengler
M Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study.
Am J Med. 1997;103483- 490
PubMedGoogle ScholarCrossref 98.Hollenbeck
CBJohnston
PVarasteh
BB
et al. Effects of metformin on glucose, insulin and lipid metabolism in patients with mild hypertriglyceridaemia and non-insulin dependent diabetes by glucose tolerance test criteria.
Diabete Metab. 1991;17483- 489
PubMedGoogle Scholar 99.Holman
RRSteemson
JTurner
RC Sulphonylurea failure in type 2 diabetes: treatment with a basal insulin supplement.
Diabet Med. 1987;4457- 462
PubMedGoogle ScholarCrossref 100.Horton
ESClinkenbeard
CGatlin
M
et al. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.
Diabetes Care. 2000;231660- 1665
PubMedGoogle ScholarCrossref 101.Hother-Nielsen
OSchmitz
OAndersen
PH
et al. Metformin improves peripheral but not hepatic insulin action in obese patients with type II diabetes.
Acta Endocrinol (Copenh). 1989;120257- 265
PubMedGoogle Scholar 102.Imano
EKanda
TNakatani
Y
et al. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy.
Diabetes Care. 1998;212135- 2139
PubMedGoogle ScholarCrossref 103.Inzucchi
SEMaggs
DGSpollett
GR
et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.
N Engl J Med. 1998;338867- 872
PubMedGoogle ScholarCrossref 104.Jackson
WPU Combined oral therapy in diabetes.
S Afr Med J. 1962;36727- 729
Google Scholar 106.Jeppesen
JZhou
MYChen
YDIReaven
GM Effect of metformin on postprandial lipemia in patients with fairly to poorly controlled NIDDM.
Diabetes Care. 1994;171093- 1099
PubMedGoogle ScholarCrossref 107.Johansen
K Acarbose treatment of sulfonylurea-treated non-insulin dependent diabetics: a double-blind cross-over comparison of an α-glucosidase inhibitor with metformin.
Diabete Metab. 1984;10219- 223
PubMedGoogle Scholar 108.Johnson
ABWebster
JMSum
CF
et al. The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients.
Metabolism. 1993;421217- 1222
PubMedGoogle ScholarCrossref 109.Johnson
MKrosnick
ACarson
PMcDade
AMLaraway
K A retrospective chart review of uncontrolled use of metformin as an add-on therapy in type 2 diabetes.
Clin Ther. 1998;20691- 698
PubMedGoogle ScholarCrossref 110.Jones
NPMather
ROwen
S
et al. Long-term efficacy of rosiglitazone as monotherapy or in combination with metformin [abstract].
Diabetologia. 2000;43
((suppl 1))
A192
Google Scholar 111.Jones
TJones
NPSautter
M Addition of rosiglitazone to metformin is effective in obese, insulin-resistant patients with type 2 diabetes [abstract].
Diabetologia. 2000;43
((suppl 1))
A191
Google Scholar 113.Josse
RG Acarbose for the treatment of type II diabetes: the results of a Canadian multi-centre trial.
Diabetes Res Clin Pract. 1995;28
((suppl))
S167- S172[published correction appears in
Diabetes Res Clin Pract. 1995;29:215].
PubMedGoogle ScholarCrossref 115.Kirk
JKPearce
KAMichielutte
RSummerson
JH Troglitazone or metformin in combination with sulfonylureas for patients with type 2 diabetes?
J Fam Pract. 1999;48879- 882
PubMedGoogle Scholar 116.Klein
WHerrmann
A Therapy of diabetes mellitus using metformin: clinical study on 60 patients [in German].
Med Welt. 1975;26516- 519
PubMedGoogle Scholar 117.Klein
W Sulfonylurea-metformin-combination versus sulfonylurea-insulin-combination in secondary failures of sulfonylurea monotherapy: results of a prospective randomized study in 50 patients.
Diabete Metab. 1991;17
((pt 2))
235- 240
PubMedGoogle Scholar 118.Lalau
JDVermersch
AHary
L
et al. Type 2 diabetes in the elderly: an assessment of metformin (metformin in the elderly).
Int J Clin Pharmacol Ther Toxicol. 1990;28329- 332
PubMedGoogle Scholar 119.Lalor
BCBhatnagar
DWinocour
PH
et al. Placebo-controlled trial of the effects of guar gum and metformin on fasting blood glucose and serum lipids in obese, type 2 diabetic patients.
Diabet Med. 1990;7242- 245
PubMedGoogle ScholarCrossref 120.Lam
KSLTiu
SCTsang
MW
et al. Acarbose in NIDDM patients with poor control on conventional oral agents.
Diabetes Care. 1998;211154- 1158
PubMedGoogle ScholarCrossref 121.Laurenti
OBravi
MCFaldetta
MCDe Mattia
G Evaluation of the efficacy of metformin-glibenclamide treatment in overweight non-insulin dependent diabetics.
Clin Ter. 1992;140259- 263
PubMedGoogle Scholar 122.Lean
MEBorthwick
LJ Ciclazindol: an oral agent with weight reducing properties and hypoglycaemic activity.
Eur J Clin Pharmacol. 1983;2541- 45
PubMedGoogle ScholarCrossref 123.Lee
AMorley
JE Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes.
Obes Res. 1998;647- 53
PubMedGoogle ScholarCrossref 124.Lord
JMWhite
SIBailey
CJ
et al. Effect of metformin on insulin receptor binding and glycaemic control in type II diabetes.
BMJ. 1983;286830- 831
PubMedGoogle ScholarCrossref 125.Lunetta
MDiMauro
M Different effect of acute and chronic oral metformin administration on glucose and insulin response to bread and to pasta in non-insulin dependent diabetic patients.
Diabetes Res Clin Pract. 1996;3353- 58
PubMedGoogle ScholarCrossref 126.Makimattila
SNikkila
KYki-Jarvinen
H Causes of weight gain during insulin therapy with and without metformin in patients with type II diabetes mellitus.
Diabetologia. 1999;42406- 412
PubMedGoogle ScholarCrossref 127.Marena
STagliaferro
VMontegrosso
G
et al. Metabolic effects of metformin addition to chronic glibenclamide treatment in type 2 diabetes.
Diabete Metab. 1994;2015- 19
PubMedGoogle Scholar 128.Marfella
RAcampora
RVerrazzo
G
et al. Metformin improves hemodynamic and rheological responses to L-arginine in NIDDM patients.
Diabetes Care. 1996;19934- 939
PubMedGoogle ScholarCrossref 129.McAlpine
LGMcAlpine
CHWaclawski
ER
et al. A comparison of treatment with metformin and gliclazide in patients with non-insulin-dependent diabetes.
Eur J Clin Pharmacol. 1988;34129- 132
PubMedGoogle ScholarCrossref 130.McBain
AMBrown
IRMenzies
DGCampbell
IW Effects of improved glycaemic control on calcium and magnesium homeostasis in type II diabetes.
J Clin Pathol. 1988;41933- 935
PubMedGoogle ScholarCrossref 131.McIntyre
HDMa
ABird
DM
et al. Metformin increases insulin sensitivity and basal glucose clearance in type 2 (non-insulin dependent) diabetes mellitus.
Aust N Z J Med. 1991;21714- 719
PubMedGoogle ScholarCrossref 132.Mehta
MJVakil
BJNarula
DVVakil
PR Utility of metformin as a non-hormonal agent in the treatment of diabetes mellitus.
J Indian Med Assoc. 1963;40151- 155
Google Scholar 133.Menzies
DGCampbell
IWMcBain
ABrown
IR Metformin efficacy and tolerance in obese non-insulin dependent diabetics: a comparison of two dosage schedules.
Curr Med Res Opin. 1989;11273- 278
PubMedGoogle ScholarCrossref 134.Moses
RSlobodniuk
RBoyages
S
et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes.
Diabetes Care. 1999;22119- 124
PubMedGoogle ScholarCrossref 135.Munk
W Treatment of obese diabetic patients using glucophage retard [in German].
Z Allgemeinmed. 1975;51681- 683
PubMedGoogle Scholar 136.Nagi
DKYudkin
JS Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects: a study of two ethnic groups.
Diabetes Care. 1993;16621- 629
PubMedGoogle ScholarCrossref 137.Nattrass
MTodd
PGHinks
L
et al. Comparative effects of phenformin, metformin and glibenclamide on metabolic rhythms in maturity-onset diabetics.
Diabetologia. 1977;13145- 152
PubMedGoogle ScholarCrossref 138.Niazi
RMuzaffar
Z Comparison of bedtime NPH insulin or metformin combined with glibenclamide in secondary sulphonylurea failure in obese type II (NIDDM) patients.
J Pak Med Assoc. 1998;48336- 338
PubMedGoogle Scholar 139.Nosadini
RAvogaro
ATrevisan
R
et al. Effect of metformin on insulin-stimulated glucose turnover and insulin binding to receptors in type 2 diabetes.
Diabetes Care. 1987;1062- 67
PubMedGoogle ScholarCrossref 140.Noury
JNandeuil
A Comparative three-month study of the efficacies of metformin and gliclazide in the treatment of NIDD.
Diabete Metab. 1991;17
((pt 2))
209- 212
PubMedGoogle Scholar 141.Ohnhaus
EEBerger
WDuckert
FOesch
F The influence of dimethylbiguanide on phenprocoumon elimination and its mode of action: a drug interaction study.
Klin Wochenschr. 1983;61851- 858
PubMedGoogle ScholarCrossref 142.Peacock
ITattersall
RB The difficult choice of treatment for poorly controlled maturity onset diabetes: tablets or insulin?
BMJ. 1984;2881956- 1959
PubMedGoogle ScholarCrossref 143.Peacock
IHawkins
MHeptinstall
S Platelet behaviour in non-insulin-dependent diabetes: influence of vascular complications, treatment and metabolic control.
Thromb Haemost. 1986;55361- 365
PubMedGoogle Scholar 144.Pedersen
J The effect of metformin on weight loss in obesity.
Acta Endocrinol. 1965;49479- 486
Google Scholar 145.Pedersen
ONielsen
OBak
J
et al. The effects of metformin on adipocyte insulin action and metabolic control in obese subjects with type 2 diabetes.
Diabet Med. 1989;6249- 256
PubMedGoogle ScholarCrossref 146.Pirart
JRutman
S A new oral antidiabetic medicine: NN dimethylbiguanide: clinical trial alternating a placebo with a sulfamide [in French].
Acta Clin Belg. 1961;16575- 589
Google Scholar 147.Ponssen
HHElte
JWLehert
P
et al. Combined metformin and insulin therapy for patients with type 2 diabetes mellitus.
Clin Ther. 2000;22709- 718
PubMedGoogle ScholarCrossref 148.Prager
RSchernthaner
GGraf
H Effect of metformin on peripheral insulin sensitivity in non insulin dependent diabetes mellitus.
Diabete Metab. 1986;12346- 350
PubMedGoogle Scholar 149.Puchegger
R Experience with the biguanide glucophage [in German].
Wien Klin Wochenschr. 1964;76335- 337
Google Scholar 150.Rains
SGWilson
GARichmond
WElkeles
RS The effect of glibenclamide and metformin on serum lipoproteins in type 2 diabetes.
Diabet Med. 1988;5653- 658
PubMedGoogle ScholarCrossref 151.Rains
SGWilson
GARichmond
WElkeles
RS The reduction of low density lipoprotein cholesterol by metformin is maintained with long-term therapy.
J R Soc Med. 1989;8293- 94
PubMedGoogle Scholar 152.Raptis
AETountas
NBYalouris
AG
et al. Therapeutic effect of glibenclamide in a fixed combination with metformin or phenformin in NIDDM patients.
Horm Metab Res. 1996;2889- 94
PubMedGoogle ScholarCrossref 153.Reaven
GMJohnston
PHollenbeck
CB
et al. Combined metformin-sulfonylurea treatment of patients with noninsulin-dependent diabetes in fair to poor glycemic control.
J Clin Endocrinol Metab. 1992;741020- 1026
PubMedGoogle Scholar 154.Relimpio
FPumar
ALosada
F
et al. Adding metformin versus insulin dose increase in insulin-treated but poorly controlled type 2 diabetes mellitus: an open-label randomized trial.
Diabet Med. 1998;15997- 1002
PubMedGoogle ScholarCrossref 155.Reyes Larrasilla
JM Chlorpropamide-dimethylbiguanide combination in the control of diabetes mellitus with complications [in Spanish].
Prensa Med Mex. 1969;34378- 381
PubMedGoogle Scholar 156.Riccio
ADel Prato
SVigili
DE
et al. Glucose and lipid metabolism in non-insulin-dependent diabetes: effect of metformin.
Diabete Metab. 1991;17
((pt 2))
180- 184
PubMedGoogle Scholar 157.Robinson
ACBurke
JRobinson
S
et al. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.
Diabetes Care. 1998;21701- 705
PubMedGoogle ScholarCrossref 158.Rodger
NWChiasson
JLJosse
RG
et al. Clinical experience with acarbose: results of a Canadian multicentre study.
Clin Invest Med. 1995;18318- 324
PubMedGoogle Scholar 159.Roger
PAuclair
JDrain
P Addition of benfluorex to biguanide improves glycemic control in obese non-insulin-dependent diabetes: a double-blind study versus placebo.
J Diabetes Complications. 1999;1362- 67
PubMedGoogle ScholarCrossref 160.Rosenstock
JBrown
AFischer
J
et al. Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes.
Diabetes Care. 1998;212050- 2055
PubMedGoogle ScholarCrossref 161.Sanchez-Barba Izquierdo
MIIbarra Rueda
JMRuiz de Adana Perez
T The combination of insulin and metformin in obese patients with type-2 diabetes mellitus.
Aten Primaria. 1999;24462- 467
PubMedGoogle Scholar 162.Santos
RFNomizo
RWajhenberg
BL
et al. Changes in insulin receptor tyrosine kinase activity associated with metformin treatment of type 2 diabetes.
Diabete Metab. 1995;21274- 280
PubMedGoogle Scholar 163.Schneider
JErren
TZofel
PKaffarnik
H Metformin-induced changes in serum lipids, lipoproteins, and apoproteins in non-insulin-dependent diabetes mellitus.
Atherosclerosis. 1990;8297- 103
PubMedGoogle ScholarCrossref 164.Schulte
JGarcia Viveros
MRull
JLozano-Castaneda
O Long-term (3 year) results of the treatment of stable diabetes with low doses of chlopropamide-metformin [in Spanish].
Prensa Med Mex. 1973;38281- 282
PubMedGoogle Scholar 165.Siedradzki
JSoszynski
P Assessment of efficacy and safety of acarbose in the treatment of diabetes mellitus: observation study in the conditions of general health care.
Przegl Lek. 1999;56335- 341
PubMedGoogle Scholar 166.Stades
AMHeikens
JTHolleman
FHoekstra
JB Effect of metformin on glycaemic control in type 2 diabetes in daily practice: a retrospective study.
Neth J Med. 2000;5686- 90
PubMedGoogle ScholarCrossref 167.Stalhammer
JBergman
UBoman
KDahlen
M Metabolic control in diabetic subjects in three Swedish areas with high, medium and low sales of antidiabetic drugs.
Diabetes Care. 1991;1412- 19
PubMedGoogle ScholarCrossref 168.Sterne
J Report on five years experience with metformin [in German].
Wien Med Wochenschr. 1963;113599- 602
Google Scholar 169.Stratmann
FW Experience with dimethylbiguanide in late failures of oral diabetes therapy [in German].
Med Welt. 1965;492743- 2746
PubMedGoogle Scholar 170.Stumvoll
MNurjhan
NPerriello
G
et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus.
N Engl J Med. 1995;333550- 554
PubMedGoogle ScholarCrossref 171.Sundaresan
PLykos
DDaher
A
et al. Comparative effects of glibenclamide and metformin on ambulatory blood pressure and cardiovascular reactivity in NIDDM.
Diabetes Care. 1997;20692- 697
PubMedGoogle ScholarCrossref 172.Swislocki
ALMKnuu
QLiao
E
et al. Safety and efficacy of metformin in a restricted formulary.
Am J Manag Care. 1999;562- 68
PubMedGoogle Scholar 174.Taylor
KGJohn
WGMatthews
KAWright
AD A prospective study of the effect of 12 months treatment on serum lipids and apolipoproteins A-I and B in type 2 (non-insulin-dependent) diabetes.
Diabetologia. 1982;23507- 510
PubMedGoogle ScholarCrossref 175.Tessari
PBiolo
GBruttomesso
D
et al. Effects of metformin treatment on whole-body and splanchnic amino acid turnover in mild type 2 diabetes.
J Clin Endocrinol Metab. 1994;791553- 1560
PubMedGoogle Scholar 176.Tessier
DMaheux
PKhalil
AFulop
T Effects of gliclazide versus metformin on the clinical profile and lipid peroxidation markers in type 2 diabetes.
Metabolism. 1999;48897- 903
PubMedGoogle ScholarCrossref 177.Testa
RBonfigli
ARPiantanelli
L
et al. Relationship between plasminogen activator inhibitor type-1 plasma levels and the lipoprotein(a) concentrations in non-insulin-dependent diabetes mellitus.
Diabetes Res Clin Pract. 1996;33111- 118
PubMedGoogle ScholarCrossref 178.Teupe
BBergis
K Prospective randomized two-years clinical study comparing additional metformin treatment with reducing diet in type 2 diabetes.
Diabete Metab. 1991;17
((pt 2))
213- 217
PubMedGoogle Scholar 179.Trischitta
VItalia
SMazzarino
S
et al. Comparison of combined therapies in treatment of secondary failure to glyburide.
Diabetes Care. 1992;15539- 542
PubMedGoogle ScholarCrossref 180.Trischitta
VItalia
SRaimondo
M
et al. Efficacy of combined treatments in NIDDM patients with secondary failure to sulphonylureas: is it predictable?
J Endocrinol Invest. 1998;21744- 747
PubMedGoogle ScholarCrossref 181.Vannasaeng
SPloybutr
SNitiyanant
W
et al. Effects of α-glucosidase inhibitor (acarbose) combined with sulfonylurea or sulfonylurea and metformin in treatment of non-insulin-dependent diabetes mellitus.
J Med Assoc Thai. 1995;78578- 585
PubMedGoogle Scholar 182.Velussi
MCernigoi
AMViezzoli
LCaffau
C Median-term (4 months) treatment with glibenclamide + metformin substituting for glibenclamide + fenformin lowers the lacticemia levels in type-2 diabetics (NIDDM) [in Italian].
Clin Ter. 1992;141483- 492
PubMedGoogle Scholar 183.Vigneri
RTrischitta
VItalia
S
et al. Treatment of NIDDM patients with secondary failure to glyburide: comparison of the addition of either metformin or bed-time NPH insulin to glyburide.
Diabete Metab. 1991;17
((pt 2))
232- 234
PubMedGoogle Scholar 184.Willey
KAMoyneaux
JEOverland
JEYue
DK The effects of dexfenfluramine on blood glucose control in patients with type 2 diabetes.
Diabet Med. 1992;9341- 343
PubMedGoogle ScholarCrossref 185.Willey
KAMolyneaux
LMYue
DK Obese patients with type 2 diabetes poorly controlled by insulin and metformin: effects of adjunctive dexfenfluramine therapy on glycaemic control.
Diabet Med. 1994;11701- 704
PubMedGoogle ScholarCrossref 186.Willms
BRuge
D Comparison of acarbose and metformin in patients with type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: a randomized, placebo-controlled study.
Diabet Med. 1999;16755- 761
PubMedGoogle ScholarCrossref 187.Wilson
JAScott
MMGray
RS A comparison of metformin versus guar in combination with sulphonylureas in the treatment of non insulin dependent diabetes.
Horm Metab Res. 1989;21317- 319
PubMedGoogle ScholarCrossref 188.Wolever
TMSRadmard
RChiasson
JL
et al. One-year acarbose treatment raises fasting serum acetate in diabetic patients.
Diabet Med. 1995;12164- 172
PubMedGoogle ScholarCrossref 189.Wolever
TMSAssiff
LBasu
T
et al. Miglitol, an α-glucosidase inhibitor, prevents the metformin-induced fall in serum folate and vitamin B12 in subjects with type 2 diabetes.
Nutr Res. 2000;201447- 1456
Google ScholarCrossref 190.Wu
MSJohnston
PSheu
WH
et al. Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients.
Diabetes Care. 1990;131- 8
PubMedGoogle ScholarCrossref 191.Wulffele
MGKooy
AOgterop
C
et al. Metformin and insulin therapy decreases glycosylated hemoglobin and insulin requirement in type 2 diabetes [abstract].
Diabetologia. 2000;43
((suppl 1))
A184
Google Scholar 192.Yki-Jarvinen
HRyysy
LNikkila
K
et al. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus: a randomized, controlled trial.
Ann Intern Med. 1999;130389- 396
PubMedGoogle ScholarCrossref 193.Yu
JGKruszynska
YTMulford
MIOlefsky
JM A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients.
Diabetes. 1999;482414- 2421
PubMedGoogle ScholarCrossref 194.Bastyr
EJStuart
CABradows
RG
et al. Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c.
Diabetes Care. 2000;231236- 1241
PubMedGoogle ScholarCrossref 195.Bauman
WAShaw
SJayatillike
E
et al. Increased intake of calcium reverses vitamin B12 malabsorption induced by metformin.
Diabetes Care. 2000;231227- 1231
PubMedGoogle ScholarCrossref 196.Charpentier
GFleury
FKabir
M
et al. Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients.
Diabet Med. 2001;18828- 834
PubMedGoogle ScholarCrossref 197.Einhorn
DRendell
MRosenzweig
J
et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study.
Clin Ther. 2000;221395- 1409
PubMedGoogle ScholarCrossref 198.Kim
Y-BCiaraldi
TPKong
A
et al. Troglitazone but not metformin restores insulin-stimulated phosphoinositide 2-kinase activity and increases p110β protein levels in skeletal muscle of type 2 diabetic subjects.
Diabetes. 2002;51443- 448
PubMedGoogle ScholarCrossref 199.Mather
KJVerma
SAnderson
TJ Improved endothelial function with metformin in type 2 diabetes mellitus.
J Am Coll Cardiol. 2001;371344- 1350
PubMedGoogle ScholarCrossref 200.Gokcel
AKarakose
HErtorer
EM
et al. Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control.
Diabetes Care. 2001;241957- 1960
PubMedGoogle ScholarCrossref 201.Standl
ESchernthaner
GRybka
J
et al. Improved glycaemic control with miglitol in inadequately controlled type 2 diabetics.
Diabetes Res Clin Pract. 2001;52205- 213
PubMedGoogle ScholarCrossref 202.Yale
J-FValiquett
TRGhazzi
MN
et al. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin.
Ann Intern Med. 2001;134737- 745
PubMedGoogle ScholarCrossref 203.Ciraldi
TPKong
APSChu
NV
et al. Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects.
Diabetes. 2002;5130- 36
PubMedGoogle ScholarCrossref 204.Hundal
RSKrssak
MDuforur
S
et al. Mechanism by which metformin reduces glucose production in type 2 diabetes.
Diabetes. 2000;492063- 2069
PubMedGoogle ScholarCrossref 205.Mughal
MZJan
MMaheri
WMMemon
MYAli
M The effect of metformin on glycemic control, serum lipids and lipoproteins in diet alone and sulfonylurea-treated type 2 diabetic patients with sub-optimal metabolic control.
J Pak Med Assoc. 2000;50381- 386
PubMedGoogle Scholar 206.Uehara
MHKohlmann
NEBZanella
MTFerreira
SRG Metabolic and haemodynamic effects of metformin in patients with type 2 diabetes mellitus and hypertension.
Diabetes Obes Metab. 2001;3319- 325
PubMedGoogle ScholarCrossref 207.Cosic
VAntic
SPesic
M
et al. Monotherapy with metformin: does it improve hypoxia in type 2 diabetic patients?
Clin Chem Lab Med. 2001;39818- 821
PubMedGoogle ScholarCrossref 208.Amador-Licona
NGuizar-Mendoza
J-MVargas
E
et al. The short-term effect of a switch from glibenclamide to metformin on blood pressure and microalbuminuria in patients with type 2 diabetes mellitus.
Arch Med Res. 2000;31571- 575
PubMedGoogle ScholarCrossref 209.Abbasi
AAKasmikha
RSotingeanu
DG Metformin-induced lacticacidemia in patients with type 2 diabetes mellitus.
Endocr Pract. 2000;6442- 446
PubMedGoogle ScholarCrossref 210.Ozata
MOktenli
CBingol
NOzdemir
IC The effects of metformin and diet on plasma testosterone and leptin levels in obese men.
Obes Res. 2001;9662- 667
PubMedGoogle ScholarCrossref 211.Van Gaal
LMaislos
MSchernthaner
G
et al. Miglitol combined with metformin improves glycaemic control in type 2 diabetes.
Diabetes Obes Metab. 2001;3326- 331
PubMedGoogle ScholarCrossref 212.Holstein
ANahrwold
DHinze
SEgbert
EH Contra-indications to metformin therapy are largely disregarded.
Diabet Med. 1999;16692- 696
PubMedGoogle ScholarCrossref 213.Aguilar
CReza
AGarcia
JERull
JA Biguanide related lactic acidosis: incidence and risk factors.
Arch Med Res. 1992;2319- 24
PubMedGoogle Scholar 214.Irsigler
KKritz
HRegal
HFoltin
E The risk of lactic acidosis: a comparison of the 3 biguanides in treatment of diabetics (authors' transl) [in German].
Wien Klin Wochenschr. 1978;90332- 337
PubMedGoogle Scholar 215.Pilger
ESchmid
PGoebel
R Effect of biguanide therapy on lactate metabolism during graded submaximal ergometric testing.
Acta Med Austriaca. 1978;591- 95
PubMedGoogle Scholar 219.Debry
GAnziani
CLaurent
J Study of lactic acid levels on an empty stomach in diabetic patients treated with N-N-dimethylbiguanide.
Diabetes. 1964;12239- 245
Google Scholar 220.Pagano
GTagliaferro
VCarta
Q
et al. Metformin reduces insulin requirement in type 1 (insulin-dependent) diabetes.
Diabetologia. 1983;24351- 354
PubMedGoogle ScholarCrossref 221.Trischitta
VGullo
DPezzino
VVigneri
R Metformin normalizes insulin binding to monocytes from obese nondiabetic subjects and obese type II diabetic patients.
J Clin Endocrinol Metab. 1983;57713- 718
PubMedGoogle ScholarCrossref 225.Gan
SCBarr
JArieff
AIPearl
RG Biguanide-associated lactic acidosis: case report and review of the literature.
Arch Intern Med. 1992;1522333- 2336
PubMedGoogle ScholarCrossref 226.Lalau
JDLacroix
CDe Cagny
BFournier
A Metformin-associated lactic acidosis in diabetic patients with acute renal failure: a critical analysis of its pathogenesis and prognosis.
Nephrol Dial Transplant. 1994;9
((suppl 4))
126- 129
PubMedGoogle Scholar